|
US6046166A
(en)
*
|
1997-09-29 |
2000-04-04 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6037323A
(en)
*
|
1997-09-29 |
2000-03-14 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6004925A
(en)
*
|
1997-09-29 |
1999-12-21 |
J. L. Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
WO2000059855A1
(en)
*
|
1999-04-01 |
2000-10-12 |
Esperion Therapeutics, Inc. |
Ether compounds, compositions, and uses thereof
|
|
US7407662B2
(en)
*
|
2000-06-29 |
2008-08-05 |
Lipid Sciences, Inc. |
Modified viral particles with immunogenic properties and reduced lipid content
|
|
AUPQ846900A0
(en)
*
|
2000-06-29 |
2000-07-27 |
Aruba International Pty Ltd |
A vaccine
|
|
US7407663B2
(en)
*
|
2000-06-29 |
2008-08-05 |
Lipid Sciences, Inc. |
Modified immunodeficiency virus particles
|
|
US20090017069A1
(en)
*
|
2000-06-29 |
2009-01-15 |
Lipid Sciences, Inc. |
SARS Vaccine Compositions and Methods of Making and Using Them
|
|
US7439052B2
(en)
*
|
2000-06-29 |
2008-10-21 |
Lipid Sciences |
Method of making modified immunodeficiency virus particles
|
|
US7148197B2
(en)
*
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
|
AU2007237157B2
(en)
*
|
2000-08-24 |
2009-04-09 |
The Regents Of The University Of California |
Peptides that ameliorate atherosclerosis
|
|
US7199102B2
(en)
*
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
US7723303B2
(en)
*
|
2000-08-24 |
2010-05-25 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
|
US7144862B2
(en)
*
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
US7166578B2
(en)
*
|
2000-08-24 |
2007-01-23 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
|
US6664230B1
(en)
*
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
DE10051983A1
(de)
*
|
2000-10-20 |
2002-06-13 |
Beate Kehrel |
Inhibierung der pathogenen Wirkung oxidierter Proteine
|
|
ES2429528T3
(es)
|
2001-01-02 |
2013-11-15 |
The Cleveland Clinic Foundation |
Mieloperoxidasa, un indicador de riesgo para enfermedad cardiovascular
|
|
US20050089932A1
(en)
*
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
US7217785B2
(en)
*
|
2001-05-09 |
2007-05-15 |
The Regents Of The University Of California |
Cysteine-containing peptides having antioxidant properties
|
|
WO2003000373A1
(en)
*
|
2001-06-25 |
2003-01-03 |
Lipid Sciences, Inc. |
Systems and methods using a solvent for the removal of lipids from fluids
|
|
WO2003000372A2
(en)
*
|
2001-06-25 |
2003-01-03 |
Lipid Sciences, Inc. |
Systems and methods using multiple solvents for the removal of lipids from fluids
|
|
US20060060520A1
(en)
*
|
2001-06-25 |
2006-03-23 |
Bomberger David C |
Systems and methods using a solvent for the removal of lipids from fluids
|
|
US20030127386A1
(en)
*
|
2001-06-25 |
2003-07-10 |
Bomberger David C. |
Hollow fiber contactor systems for removal of lipids from fluids
|
|
US6991727B2
(en)
*
|
2001-06-25 |
2006-01-31 |
Lipid Sciences, Inc. |
Hollow fiber contactor systems for removal of lipids from fluids
|
|
WO2003026492A2
(en)
*
|
2001-09-28 |
2003-04-03 |
Esperion Therapeutics Inc. |
Prevention and treatment of restenosis by local administration of drug
|
|
PL369545A1
(pl)
*
|
2001-09-28 |
2005-05-02 |
Esperion Therapeutics, Inc. |
Sposoby i urządzenia do wytłaczania pęcherzyków pod wysokim ciśnieniem
|
|
US6930085B2
(en)
*
|
2002-04-05 |
2005-08-16 |
The Regents Of The University Of California |
G-type peptides to ameliorate atherosclerosis
|
|
US20040009216A1
(en)
*
|
2002-04-05 |
2004-01-15 |
Rodrigueza Wendi V. |
Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
|
|
US20100204103A1
(en)
*
|
2002-05-08 |
2010-08-12 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
|
IL165253A0
(en)
*
|
2002-05-17 |
2005-12-18 |
Esperion Therapeutics Inc |
Methods and compositions for the treatment of ischemic reperfusion
|
|
BR0310099A
(pt)
*
|
2002-05-17 |
2007-03-20 |
Esperion Therapeutics Inc |
método para tratar dislipidemia ou uma doença associada com a dislipidemia
|
|
EP1545576A2
(en)
*
|
2002-07-30 |
2005-06-29 |
Esperion Therapeutics Inc. |
Methods of using non-human animal apoliprotein a-i protein
|
|
EP1534243A4
(en)
*
|
2002-08-26 |
2008-08-13 |
Lipid Sciences Inc |
TREATMENT OF ALZHEIMER WITH ENTLIPIDED PROTEIN PARTICLES
|
|
MXPA05007674A
(es)
*
|
2003-01-23 |
2005-09-22 |
Esperion Therapeutics Inc |
Compuestos de hidroxilo y composiciones para el manejo del colesterol y usos relacionados.
|
|
JP2007534612A
(ja)
*
|
2003-04-22 |
2007-11-29 |
アバニール・ファーマシューティカルズ |
高コレステロール血症の治療のためのコレステロール逆輸送メディエータ
|
|
US7393826B2
(en)
*
|
2003-07-03 |
2008-07-01 |
Lipid Sciences, Inc. |
Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
|
|
PT1641421T
(pt)
*
|
2003-07-03 |
2019-03-27 |
Hdl Therapeutics Inc |
Métodos e dispositivos para criar derivados de partículas de hdl com conteúdo de lípidos reduzido
|
|
US7459286B1
(en)
|
2003-10-22 |
2008-12-02 |
The Cleveland Clinic Foundation |
Assessing the risk of a major adverse cardiac event in patients with chest pain
|
|
US6960803B2
(en)
*
|
2003-10-23 |
2005-11-01 |
Silicon Storage Technology, Inc. |
Landing pad for use as a contact to a conductive spacer
|
|
EP2306192B1
(en)
*
|
2003-12-05 |
2015-10-14 |
The Cleveland Clinic Foundation |
Risk Markers For Cardiovascular Disease
|
|
AU2004299486B2
(en)
*
|
2003-12-15 |
2011-05-19 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
|
EP1699527A1
(en)
|
2004-01-02 |
2006-09-13 |
Advanced Cardiovascular Systems, Inc. |
High-density lipoprotein coated medical devices
|
|
WO2005097206A2
(en)
*
|
2004-04-06 |
2005-10-20 |
Cedars-Sinai Medical Center |
Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
|
|
US7378396B2
(en)
|
2004-08-11 |
2008-05-27 |
The Cleveland Clinic Foundation |
Therapeutic agents and methods for cardiovascular disease
|
|
WO2006034056A2
(en)
*
|
2004-09-16 |
2006-03-30 |
The Regents Of The University Of California |
G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
|
|
WO2006049597A1
(en)
*
|
2004-10-27 |
2006-05-11 |
Avanir Pharmaceuticals |
Amino acid-derived compounds as modulators of the reverse cholesterol transport
|
|
BRPI0517148A
(pt)
|
2004-12-06 |
2008-09-30 |
Univ California |
método de aperfeiçoamento da estrutura e/ou função arterìola; agente ativo e kit para tratamento
|
|
WO2006069371A1
(en)
*
|
2004-12-22 |
2006-06-29 |
Baylor College Of Medicine |
A method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
|
|
US7759315B2
(en)
|
2005-03-09 |
2010-07-20 |
Csl Behring Ag |
Treatment of inflammatory conditions of the intestine
|
|
US8206750B2
(en)
|
2005-03-24 |
2012-06-26 |
Cerenis Therapeutics Holding S.A. |
Charged lipoprotein complexes and their uses
|
|
EP1890715A4
(en)
*
|
2005-04-29 |
2009-10-28 |
Univ California |
PEPTIDES AND PEPTIDE MIMETICS FOR TREATMENT BY INFLAMMATORY REACTION OF CHARACTERIZED PATHOLOGIES
|
|
US20080293639A1
(en)
*
|
2005-04-29 |
2008-11-27 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
|
NZ565955A
(en)
|
2005-08-22 |
2011-08-26 |
Melior Pharmaceuticals I Inc |
Methods and formulations for modulating lyn kinase activity and treating related disorders
|
|
US20070254832A1
(en)
*
|
2006-02-17 |
2007-11-01 |
Pressler Milton L |
Methods for the treatment of macular degeneration and related eye conditions
|
|
WO2007137400A1
(en)
*
|
2006-06-01 |
2007-12-06 |
Institut De Cardiologie De Montreal |
Method and compound for the treatment of valvular stenosis
|
|
US20080227686A1
(en)
*
|
2006-06-16 |
2008-09-18 |
Lipid Sciences, Inc. |
Novel Peptides that Promote Lipid Efflux
|
|
US20080206142A1
(en)
*
|
2006-06-16 |
2008-08-28 |
Lipid Sciences, Inc. |
Novel Peptides That Promote Lipid Efflux
|
|
WO2007149355A2
(en)
*
|
2006-06-16 |
2007-12-27 |
Lipid Sciences, Inc. |
Novel peptides that promote lipid efflux
|
|
CA2659655A1
(en)
|
2006-08-08 |
2008-02-21 |
Alan M. Fogelman |
Salicylanilides enhance oral delivery of therapeutic peptides
|
|
US20080138284A1
(en)
*
|
2006-09-26 |
2008-06-12 |
Lipid Sciences, Inc. |
Novel Peptides That Promote Lipid Efflux
|
|
US8541236B2
(en)
*
|
2006-12-08 |
2013-09-24 |
University Of Washington |
Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
|
|
WO2008094905A2
(en)
*
|
2007-01-29 |
2008-08-07 |
Lipid Sciences, Inc. |
Encapsulated hdl mimetic peptides
|
|
CA2931881C
(en)
*
|
2007-01-31 |
2018-12-11 |
Nutrition 21, Inc. |
Use of chromium histidinate for treatment of cardiometabolic disorders
|
|
KR20100014480A
(ko)
*
|
2007-02-20 |
2010-02-10 |
멜리어 파마슈티칼스 아이, 인코포레이티드 |
Ｌｙｎ 키나제 활성제의 확인 방법
|
|
EP2465519B1
(en)
|
2007-03-01 |
2013-10-23 |
CSL Limited |
Treatment of endothelial dysfunction in diabetic patients
|
|
ES2579229T3
(es)
|
2007-03-13 |
2016-08-08 |
Jds Therapeutics, Llc |
Procedimientos y composiciones para la liberación sostenida de cromo
|
|
WO2009002867A2
(en)
|
2007-06-26 |
2008-12-31 |
Nutrition 21, Inc. |
Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
|
|
NZ579288A
(en)
*
|
2007-07-23 |
2012-06-29 |
Melior Discovery Inc |
Methods of activating irs-1 and akt
|
|
WO2009032693A2
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
|
US8557767B2
(en)
|
2007-08-28 |
2013-10-15 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
|
US7985727B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Apo A-I mimetic peptides and methods of treatment
|
|
US8101565B2
(en)
|
2007-09-20 |
2012-01-24 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US8044021B2
(en)
|
2007-09-20 |
2011-10-25 |
Abbott Cardiovascular Systems Inc. |
Sustained release of apo A-I mimetic peptides and methods of treatment
|
|
US7985728B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US9173890B2
(en)
|
2007-09-20 |
2015-11-03 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US8552184B2
(en)
*
|
2008-07-03 |
2013-10-08 |
Melior Pharmaceuticals I, Inc. |
Compounds and methods for treating disorders related to glucose metabolism
|
|
US8241861B1
(en)
|
2008-07-08 |
2012-08-14 |
Insilicos, Llc |
Methods and compositions for diagnosis or prognosis of cardiovascular disease
|
|
SG10201901089TA
(en)
|
2008-11-10 |
2019-03-28 |
Arbutus Biopharma Corp |
Novel lipids and compositions for the delivery of therapeutics
|
|
EP3243504A1
(en)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
|
SI2396017T1
(sl)
|
2009-02-16 |
2015-12-31 |
Cerenis Therapeutics Holding Sa |
Mimika apolipoproteina A-1
|
|
AU2010223967B2
(en)
|
2009-03-12 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
|
SG10201402054UA
(en)
|
2009-05-05 |
2014-09-26 |
Muthiah Manoharan |
Lipid compositions
|
|
HUE056773T2
(hu)
|
2009-06-10 |
2022-03-28 |
Arbutus Biopharma Corp |
Továbbfejlesztett lipid készítmény
|
|
AP2015008874A0
(en)
|
2009-08-14 |
2015-11-30 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
|
US20120270771A1
(en)
*
|
2009-09-30 |
2012-10-25 |
Snu R&Db Foundation |
Apolipoprotein a-1 mimic peptides, and therapeutic agent for treating hyperlipidemia and diseases related to hyperlipidemia comprising same
|
|
WO2011044545A2
(en)
|
2009-10-09 |
2011-04-14 |
Sigalov Alexander B |
Methods and compositions for targeted imaging
|
|
US10894098B2
(en)
|
2012-04-09 |
2021-01-19 |
Signablok, Inc. |
Methods and compositions for targeted imaging
|
|
WO2011071860A2
(en)
|
2009-12-07 |
2011-06-16 |
Alnylam Pharmaceuticals, Inc. |
Compositions for nucleic acid delivery
|
|
AU2010330814B2
(en)
|
2009-12-18 |
2017-01-12 |
Acuitas Therapeutics Inc. |
Methods and compositions for delivery of nucleic acids
|
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
WO2011143362A1
(en)
|
2010-05-11 |
2011-11-17 |
Esperion Therapeutics, Inc. |
Dimeric oxidation-resistant apolipoprotein a1 variants
|
|
US20130158055A1
(en)
|
2010-05-28 |
2013-06-20 |
Andrew G. Reaume |
Prevention Of Pancreatic Beta Cell Degeneration
|
|
IL300109A
(en)
|
2010-06-03 |
2023-03-01 |
Alnylam Pharmaceuticals Inc |
Biodegradable lipids for the transfer of active substances
|
|
US20130323269A1
(en)
|
2010-07-30 |
2013-12-05 |
Muthiah Manoharan |
Methods and compositions for delivery of active agents
|
|
US20130202652A1
(en)
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
EP2611419A2
(en)
|
2010-08-30 |
2013-07-10 |
F.Hoffmann-La Roche Ag |
Method for producing a tetranectin-apolipoprotein a-1 lipid particle, the lipid particle itself and its use
|
|
CN110123830A
(zh)
|
2010-11-09 |
2019-08-16 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
|
EP3202760B1
(en)
|
2011-01-11 |
2019-08-21 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
|
RU2017126088A
(ru)
|
2011-02-07 |
2019-01-31 |
Серени Терапеутикс Холдинг С.А. |
Липопротеиновые комплексы и их получение и применения
|
|
CA2828572C
(en)
|
2011-03-01 |
2021-02-23 |
Jds Therapeutics, Llc |
Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
|
|
AU2012315965A1
(en)
|
2011-09-27 |
2014-04-03 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted PEGylated lipids
|
|
CA2859156C
(en)
|
2011-12-12 |
2020-10-06 |
Melior Pharmaceuticals I, Inc. |
Treatment of type i and type ii diabetes
|
|
CN103073646A
(zh)
*
|
2012-03-13 |
2013-05-01 |
华中科技大学 |
一种运载蜂毒肽的多肽、运载蜂毒肽的纳米颗粒及其应用
|
|
CA2902209A1
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Peptides having reduced toxicity that stimulate cholesterol efflux
|
|
EP2853259A1
(en)
|
2013-09-30 |
2015-04-01 |
Université Pierre et Marie Curie (Paris 6) |
Reconstituted high density lipoproteins composition and uses thereof
|
|
EP3137899A2
(en)
|
2014-05-02 |
2017-03-08 |
Cerenis Therapeutics Holding SA |
Hdl therapy markers
|
|
US10220046B2
(en)
|
2014-07-14 |
2019-03-05 |
The Regents Of The University Of Michigan |
Compositions and methods for disease treatment using nanoparticle delivered compounds
|
|
EP3189069B1
(en)
|
2014-07-31 |
2024-10-23 |
UAB Research Foundation |
Apoe mimetic peptides and higher potency to clear plasma cholesterol
|
|
WO2016123365A1
(en)
|
2015-01-30 |
2016-08-04 |
The Regents Of The University Of Michigan |
Liposomal particles comprising biological molecules and uses thereof
|
|
CN107530307A
(zh)
|
2015-03-13 |
2018-01-02 |
艾斯柏伦治疗公司 |
包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法
|
|
MA41793A
(fr)
|
2015-03-16 |
2018-01-23 |
Esperion Therapeutics Inc |
Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
|
|
CA2979712C
(en)
|
2015-03-25 |
2024-01-23 |
The Regents Of The University Of Michigan |
Nanoparticle compositions for delivery of biomacromolecules
|
|
WO2017139337A1
(en)
|
2016-02-11 |
2017-08-17 |
Nutrition 21, Llc |
Chromium containing compositions for improving health and fitness
|
|
US11027052B2
(en)
|
2017-11-22 |
2021-06-08 |
HDL Therapuetics, Inc. |
Systems and methods for priming fluid circuits of a plasma processing system
|
|
NZ758966A
(en)
|
2017-04-10 |
2024-08-30 |
Board Of Supervisors Of Louisiana State Univ And Agricultural And Mechanical College |
Treatment of adipocytes
|
|
US20190048049A1
(en)
|
2017-08-10 |
2019-02-14 |
Cerenis Therapeutics Holding Sa |
Cargomers
|
|
EP3731814A4
(en)
|
2017-12-28 |
2021-09-29 |
HDL Therapeutics, Inc. |
PROCESSES FOR THE STORAGE AND ADMINISTRATION OF HIGH DENSITY PRE-BETA LIPOPROTEINS EXTRACTED FROM HUMAN PLASMA
|
|
EP3986860A1
(en)
|
2019-06-21 |
2022-04-27 |
Esperion Therapeutics, Inc. |
Salt forms of bempedoic acid and methods for using the same
|
|
AU2021256086A1
(en)
|
2020-04-16 |
2022-12-15 |
Abionyx Pharma Sa |
Methods for treating acute conditions using lipid binding protein- based complexes
|
|
WO2022069942A2
(en)
|
2020-10-01 |
2022-04-07 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
|
MX2023012223A
(es)
|
2021-04-15 |
2023-10-26 |
Abionyx Pharma Sa |
Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos.
|
|
WO2023194798A1
(en)
|
2022-04-06 |
2023-10-12 |
Abionyx Pharma Sa |
Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
|
|
WO2023194797A1
(en)
|
2022-04-06 |
2023-10-12 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
|
WO2023237927A2
(en)
|
2022-06-10 |
2023-12-14 |
Abionyx Pharma Sa |
Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
|
|
WO2023237935A2
(en)
|
2022-06-10 |
2023-12-14 |
Abionyx Pharma Sa |
Methods for treating acute conditions using lipid binding protein-based complexes
|
|
WO2024150064A1
(en)
|
2023-01-13 |
2024-07-18 |
Abionyx Pharma Sa |
Lipid binding protein molecule therapy
|